Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of High Daily Dose Short Course Primaquine After G6PD Testing for the Radical Cure of Plasmodium Vivax Malaria

NCT05879224 is registered in ClinicalTrials.gov with Menzies School of Health Research as lead sponsor.

NCT NCT05879224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of High Daily Dose Short Course Primaquine After G6PD Testing for the Radical Cure of Plasmodium Vivax Malaria
Lead sponsor
Menzies School of Health Research
Phase
Not applicable
Overall status
Completed
Start date
August 7, 2023
Completion date
December 17, 2025
Enrollment
2,999 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

g6pd deficiency, vivax malaria